Back to Search
Start Over
Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy.
Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy.
- Source :
-
BMC infectious diseases [BMC Infect Dis] 2016 Feb 01; Vol. 16, pp. 55. Date of Electronic Publication: 2016 Feb 01. - Publication Year :
- 2016
-
Abstract
- Background: Viral infections such as influenza are thought to impact respiratory parameters and to promote infection with Pseudomonas aeruginosa in patients with cystic fibrosis (CF). However, the real morbidity of the influenza virus in CF needs to be further investigated because previous studies were only observational.<br />Methods: CF patients were included in a case-control study (n = 44 cases and n = 371 controls) during the 2009 pandemic A/H1N1 influenza. Cases were patients with polymerase reaction chain-confirmed influenza A/H1N1 infection. Controls did not report any influenza symptoms during the same period. Sputum colonization and lung function were monitored during 1 year after inclusion.<br />Results: Cases were significantly younger than controls (mean(SD) 14.9 years(11) versus 20.1 years (13.2) and significantly less frequently colonized with P. aeruginosa (34 % versus 53 %). During influenza infection, 74 % of cases had pulmonary exacerbation, 92 % had antibiotics adapted to their usual sputum colonization and 82 % were treated with oseltamivir. Two cases required lung transplantation after A/H1N1 infection (one had not received oseltamivir and the other one had been treated late). The cases received a mean number of antibiotic treatments significantly higher during the year after the influenza infection (mean(SD) 2.8 (2.4) for cases versus 1.8(2.1) for controls; p = 0.002). An age-matched comparison did not demonstrate any significant modification of bronchopulmonary bacterial colonization during the year after influenza infection nor any significant change in FEV1 at months 1, 3 and 12 after A/H1N1 infection.<br />Conclusions: Our results do not demonstrate any change in sputum colonization nor significant lung disease progression after pandemic A/H1N1 influenza.<br />Trial Registration: Clinical Trials.gov registration number: NCT01499914.
- Subjects :
- Adolescent
Adult
Anti-Bacterial Agents therapeutic use
Antiviral Agents therapeutic use
Case-Control Studies
Child
Child, Preschool
Cystic Fibrosis complications
Cystic Fibrosis genetics
Cystic Fibrosis Transmembrane Conductance Regulator genetics
Female
Humans
Influenza A Virus, H1N1 Subtype genetics
Influenza, Human complications
Influenza, Human drug therapy
Male
Mutation
Oseltamivir therapeutic use
Prospective Studies
Pseudomonas Infections drug therapy
Pseudomonas Infections microbiology
Sputum microbiology
Young Adult
Cystic Fibrosis microbiology
Influenza A Virus, H1N1 Subtype isolation & purification
Influenza, Human epidemiology
Pandemics
Pseudomonas Infections epidemiology
Pseudomonas aeruginosa isolation & purification
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2334
- Volume :
- 16
- Database :
- MEDLINE
- Journal :
- BMC infectious diseases
- Publication Type :
- Academic Journal
- Accession number :
- 26830335
- Full Text :
- https://doi.org/10.1186/s12879-016-1352-2